Access Industries has led a $46.5m series A round for Ada Health, the developer of an app that helps users understand their health condition and recommends treatments.

The Cornell University spinout will look at inhibitor drugs that could better fight autoimmune and inflammatory diseases.

Nucana secured nearly $100m in its flotation on Nasdaq, slightly below its target of $115m, though its shares had climbed from an opening price of $15 to $18.37 by the end of the week.

Johnson & Johnson-backed medical technology producer NeuroPace has added $74m in funding in a round co-led by Orbimed and KCK Group.

The subcutaneous drug developer has raised more than $77m in financing from investors including Sun Pharmaceutical Industries and Lundbeck since 2014.

The corporate venturing unit has launched a second fund, just over three years after putting $100m into its first.

The University of Warwick spinout is developing treatments for respiratory conditions such as influenza.

Takeda Ventures has hired Jayson Punwani from Pappas Ventures as an investment director.

The GV-backed immunotherapy developer has filed for a $57.5m initial public offering that will come after $95m of venture financing.